Evicenter
Cobenfy (xanomeline and trospium chloride) in Schizophrenia
Manufacturer
Bristol-Myers Squibb Company
Prescribing information
Cobenfy (opens in a new tab)
Questions
38
Last updated

All questions

Safety: Cobenfy (xanomeline and trospium chloride) in schizophrenia

13 questions · 4 sources

Monitoring

What monitoring does COBENFY require before and during treatment?

Safety

Does COBENFY raise liver enzymes?

What are the most common COBENFY side effects?

Does COBENFY cause nausea and vomiting?

Which less common COBENFY side effects (2% to under 5%) were seen in short- and long-term trials?

Note: The page shows the more common pooled adverse reactions as a chart, which is not quoted. The page text does not label which of the two rates given for each reaction is short-term and which is long-term.

Does COBENFY have a boxed warning?

What happens with a COBENFY overdose?

Can COBENFY cause urinary retention?

Does COBENFY cause weight gain?

Note: The ~96% figure comes from pooled data of the 52-week, open-label EMERGENT-4 and EMERGENT-5 trials named in the page reference list; the page reports it without a placebo or active comparator group. About 4% of patients had a weight increase of 7% or more.

Does COBENFY cause movement disorders or extrapyramidal symptoms (EPS)?

Note: The long-term trials of COBENFY were 52-week, open-label studies.

What are the contraindications for COBENFY?

Safety management

How are nausea and vomiting on COBENFY managed?

Warnings

What are the COBENFY warnings and precautions?